FindTrial
Sign In

A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg administered every 28 days for 6 months in acromegalic patients with uncontrolled disease

A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg administered every 28 days for 6 months in acromegalic patients with uncontrolled disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003444-53-IT
Enrollment
50
Registered
2005-12-15
Start date
2005-10-11
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of acromegalic patients partially responsive to somatostatin analogues MedDRA version: 6.1 Level: PT Classification code 10000599

Interventions

Trade Name: SANDOSTATINA LAR 30MG/2,5MLS Pharmaceutical Form: Powder and solvent for suspension for injection INN or Proposed INN: Octreotide CAS Number: 83150-76-9 Concentration unit: mg milligram(s)

Sponsors

NOVARTIS FARMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026